Skip to main content

Table 2 Changes from baseline in inflammatory indices, dose of corticosteroids, and visual acuity

From: Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study

  All (n= 28) Group 1 (n= 14) Group 2 (n= 14)
Baseline Month 3 Month 6 Baseline Month 3 Month 6 Baseline Month 3 Month 6
Anterior chamber cells (number of patients)          
 None 24 26 27 11 13 14 13 13 13
 0.5+ 3 2 1 2 1 - 1 1 1
 1+ 1 - - 1 - - - - -
 2+ - - - - - - - - -
 3+ - - - - - - - - -
 4+ - - - - - - - - -
Vitreous cells (number of patients)          
 None 14 22 27 8 11 11 6 11 11
 0.5+ 5 5 1 3 3 2 2 2 1
 1+ 7 1 - 3 - 1 4 1 2
 2+ 2 - - - - - 2 - -
 3+ - - - - - - - - -
 4+ - - - - - - - - -
Vitreous haze (number of patients)          
 None - 13 7 - 6 3 - 7 4
 0.5+ 8 11 16 3 6 9 5 5 7
 1+ 11 4 5 7 2 2 4 2 3
 2+ 8 - - 3 - - 5 - -
 3+ 1 - - 1 - - - - -
 4+ - - - - - - - - -
Corticosteroids dose (median mg/day ± SD)          
 Category 1 (n = 7) NA NA NA NA NA NA NA NA NA
 Category 2 (n = 13) 20 ± 15.7 12.5 ± 6.8 8 ± 5.7 25 ± 18.1 13.8 ± 8 7.8 ± 7.1 20 ± 11.4 12.5 ± 4.5 8.0 ± 1.9
 Category 3 (n = 7) 9 ± 3.1 4 ± 2.9 3 ± 2.2 8.0 ± 2.1 4.0 ± 2.5 3.0 ± 1.8 9.0 ± 4.0 5.5 ± 3.5 3.0 ± 2.6
Visual acuity (mean ±SD)          
 Category 1 62 ± 13.3 66 ± 13.1 61 ± 14.5 55 ± 6.2 59 ± 12.7 51 ± 10.6 68 ± 15.4 72 ± 11.5 69 ± 12.8
 Category 2 71 ± 16.8 72 ± 16.3 72 ± 18.1 69 ± 15.3 70 ± 14.4 69 ± 16.9 73 ± 20.6 77 ± 20.1 76 ± 21.3
 Category 3 72 ± 22.6 74 ± 18.3 74 ± 15.8 66 ± 23.1 71 ± 16.3 69 ± 14 75 ± 24.2 77 ± 21 76 ± 17.8
  1. n, number; SD, standard deviation; NA, not applicable.